A Study of Two Formulations of Ixekizumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

245

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

February 19, 2021

Study Completion Date

February 19, 2021

Conditions

Healthy

Interventions

DRUG

Ixekizumab

Administered SC.

Trial Locations (4)

Covance Clinical Research Inc, Daytona Beach

Miami Research Associates, Miami

Covance Clinical Research Inc, Madison

Covance Dallas, Dallas

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04259346 - A Study of Two Formulations of Ixekizumab in Healthy Participants | Biotech Hunter | Biotech Hunter